CAMBRIDGE, UK, March 17, 2026
Mestag Therapeutics has announced a $40 million financing round to advance its first-in-class oncology candidate MST-0312 into clinical development, alongside key leadership appointments to support its transition into the clinic. The funding, backed by SV Health Investors, Johnson & Johnson Innovation, Forbion, GV (Google Ventures), and Northpond Ventures, brings total capital raised to over $95 million, underscoring strong investor confidence in the company’s fibroblast immunology platform and novel antibody pipeline.
Financing Supports Phase 1 STARLYS Clinical Trial
The proceeds from the financing will directly support the Phase 1 STARLYS clinical trial, expected to begin in mid-2026, evaluating MST-0312, a FAP-targeted bispecific antibody designed to activate the lymphotoxin-β receptor (LTBR). This innovative mechanism is intended to induce tertiary lymphoid structures (TLS) and high endothelial venules (HEV) within tumors, biological features associated with enhanced immune response and improved survival outcomes in cancer patients. MST-0312 represents a first- and best-in-class therapeutic approach, particularly targeting tumors that are resistant to conventional immunotherapies, marking a significant advancement in oncology drug development.
The transition into clinical trials highlights a critical milestone aligned with Good Clinical Practice (GCP) standards, emphasizing the importance of clinical protocol design, patient safety, and regulatory compliance. This combination of venture funding and clinical progression makes the development highly relevant for both investment and regulatory-focused audiences.
Leadership Expansion to Drive Clinical and Regulatory Strategy
Advertisement
To support its clinical ambitions, Mestag has strengthened its leadership team with the appointment of Dr. Lindsey Rolfe as Chief Medical Officer and Dr. Pascal Merchiers as Chief Development Officer. Both executives bring extensive experience in clinical development, regulatory affairs, and biologics innovation, which will be crucial in guiding MST-0312 through early-stage trials and beyond.
Dr. Rolfe has led multiple global development programs and played key roles in achieving regulatory approvals, while Dr. Merchiers brings over 25 years of experience in drug discovery and translational research across oncology and inflammatory diseases. Their expertise will help ensure efficient clinical execution, regulatory alignment, and strategic pipeline advancement, reinforcing Mestag’s readiness to enter the clinical stage.
Integrated Platform and Strategic Partnerships Enhance Growth
Mestag’s pipeline is built on its proprietary RAFT platform, which focuses on fibroblast-immune interactions to identify and develop novel therapeutic targets. In addition to MST-0312, the company is advancing programs targeting both oncology and inflammatory diseases, reflecting a diversified and scalable innovation strategy.
The company has also established collaborations with major pharmaceutical players, including Johnson & Johnson and MSD, validating its scientific approach and supporting further research and development. This integration of venture capital funding, platform innovation, and strategic partnerships positions Mestag to accelerate both clinical progress and long-term pipeline expansion.
The $40 million financing secured by Mestag Therapeutics, combined with its advancement into Phase 1 clinical trials, represents a significant milestone at the intersection of venture capital and clinical innovation. By leveraging strong investor backing and a differentiated scientific platform, the company is poised to deliver next-generation immuno-oncology therapies for patients with limited treatment options. This development highlights the growing importance of VC-driven clinical advancement in biopharma, making it highly relevant for stakeholders across both investment and regulatory landscapes.
Source: Mestag Therapeutics press release
